Open rings of demyelination – a rare case of tumefactive multiple sclerosis
DOI:
https://doi.org/10.15584/ejcem.2025.3.10Keywords:
case report, demyelination, neuroimaging, open ring-enhancing lesion, stroke mimic, tumefactive MSAbstract
Introduction and aim. Tumefactive multiple sclerosis (MS), a rare and atypical subtype of MS, presents with large demyelinating lesions that can mimic acute stroke, leading to diagnostic uncertainty. Stroke-like symptoms in such cases require a thorough neuroimaging. We describe the case of a 35-year-old woman who presented with acute onset of right-sided hemiparesis and hemisensory loss, along with facial weakness of the left upper motor neuron facial weakness and focal seizures. Initially suspected to be a cerebrovascular event, the condition was later diagnosed as tumefactive multiple sclerosis.
Description of the case. Comprehensive neurological assessment with neuroimaging and magnetic resonance peduncle, and bilateral cerebral hemispheres, raising suspicion of a demyelinating process. A differential diagnosis, including neoplastic, infectious, and inflammatory conditions was carefully evaluated before confirming tumefactive MS. The patient’s stroke-like deficits improved significantly with high-dose intravenous methylprednisolone therapy. Follow-up imaging demonstrated the resolution of the enhancing lesions, strengthening the diagnosis. The dramatic response to steroids and the absence of progressive deterioration helped differentiate tumefactive MS from gliomas or infectious abscesses.
Conclusion. This case highlights the importance of considering tumefactive MS in acute neurological deficits with ring-enhancing lesions. Advanced imaging techniques are crucial for accurate differentiation that allows for timely and appropriate treatment.
Downloads
References
Peker E, Ünal S, Uludağ SB, Zorlu NSY. Ring-Enhancing Lesions-Differentiation with MRI. Br J Hosp Med (Lond). 2024;85(10):1-20. doi:10.12968/hmed.2024.0195
Fereidan-Esfahani M, Decker PA, Eckel Passow JE, Lucchinetti CF, Flanagan EP, Tobin WO. Population-based incidence and clinical-radiological characteristics of tumefactive demyelination in Olmsted County, Minnesota, United States. Eur J Neurol. 2022;29(3):782-789. doi:10.1111/ene.15182
Al Malik YM. Tumefactive demyelinating lesions: A literature review of recent findings. Neurosciences Journal. 2024;29(3):153. doi:10.17712/nsj.2024.3.20230111
Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278-86. doi:10.1212/wnl.0000000000000560
Tosunoğlu B, Gökçe ÇB, Nalan GH, Nilay K, and Yoldaş TK. Tumefactive multiple sclerosis. Baylor University Medical Center Proceedings. 2024;37(2):344-347. doi: 10.1080/08998280.2023.2289301
Balloy G, Pelletier J, Suchet L, et al. Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients. J Neurol. 2018;265(10):2251-2259. doi: 10.1007/s00415-018-8984-7
Zaheer K, Ajmeri AN, Singh M, Suliman MS, Teka S. Tumefactive Multiple Sclerosis, A Rare Variant Presenting as Multiple Ring-enhancing Lesions in an Immunocompetent Patient: A Case Report. Cureus. 2018;10(12):e3738. doi: 10.7759/cureus.3738
ElSaygh J, Kandinova N, Zaher A, Sunner GK, Kostanyan S. Tumefactive Multiple Sclerosis: Challenges With Treatment Modalities. Cureus. 2023;15(7):e41845. doi: 10.7759/cureus.41845
Algahtani H, Shirah B, Alassiri A. Tumefactive demyelinating lesions: A comprehensive review. Mult Scler Relat Disord. 2017;14:72-79. doi: 10.1016/j.msard.2017.04.003
Nakayama M, Naganawa S, Ouyang M, et al. A Review of Clinical and Imaging Findings in Tumefactive Demyelination. AJR Am J Roentgenol. 2021/07/01 2021;217(1):186-197. doi:10.2214/AJR.20.23226
Altintas A, Petek B, Isik N, et al. Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study. Mult Scler. 2012;18(10):1448-1453. doi: 10.1177/1352458512438237
French HD. Tumefactive multiple sclerosis versus high-grade glioma: A diagnostic dilemma. Surg Neurol Int. 2021;12:199. doi: 10.25259/sni_901_2020
Fereidan-Esfahani M, Tobin WO. Cyclophosphamide in treatment of tumefactive multiple sclerosis. Mult Scler Relat Disord. 2021;47. doi:10.1016/j.msard.2020.102627
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 European Journal of Clinical and Experimental Medicine

This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.




